WHO director-general rebuts US criticism, plans to cut budget
Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US governmentâs accusations against the global.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, has given a four-point rebuttal to the US governmentâs accusations against the global.
Global researchers, led by Australiaâs Macquarie University, in a bid to re-engineer life in a laboratory, have completed the worldâs first synthetic yeast.
Bharti Jayshankar February 1, 2025: A study published in JAMA Network Open reveals that heavy cannabis use may impair brain function during critical.
Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinsonâs.
Vertex Pharmaceuticals Inc.âs non-opioid analgesic to treat moderate to severe acute pain in adults got approval from the US drug regulator.
Britainâs National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to.
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its ârobust efficacy,â according.
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an âEmergency Humanitarian Waiverâ to allow.
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a âlack of foreseeable clinical benefit,â according to.
Novo Nordiskâs medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.